Oxeltis Ranked One Of The Fastest Growing Companies In The 2015 Deloitte In Extenso Technology Fast 50
Secured 30th position after a 559% revenue growth between 2011 and 2014, expects 50% increase in 2014-2015
Oxeltis has built a loyal international client base with its highly responsive service, its non-disclosure policy and strong scientific expertise in niche areas of medicinal chemistry
Montpellier, France, November 26, 2015 – Oxeltis, a medicinal chemistry and custom synthesis company, today announces that it has been ranked 30th in the 2015 Deloitte In Extenso Technology Fast 50 for France. The ranking is an award program for the fastest-growing technology businesses, selected on the rate of revenue growth over the last four financial years. Oxeltis grew by 559% between 2011 and 2014, securing its ranking as 30th amongst the 460 businesses that applied this year.
Founded in 2010, Oxeltis specializes in the development of small-scale custom synthesis and in hit and lead optimization programs; predominantly in the areas of antivirals, antibiotics and anticancer agents. The company has grown exponentially over the last four years after developing its custom synthesis business in a small number of niche areas such as the synthesis of natural molecule analogues for therapeutic use, especially anti-infective drugs. Its experienced team gives the company a distinct advantage in the highly competitive international market. Oxeltis has been able to win new business against European and Asian competitors by controlling overall operating costs and developing a simple and responsive organizational structure.
“Five years after it was founded as a medicinal chemistry services company, Oxeltis has gradually expanded its business in the highly competitive European and international markets,” said Jean-Marc Allaire, CEO of Oxeltis. “We are proud to have been selected by Deloitte. Our inclusion acknowledges the work of Oxeltis’ team of chemists. I applaud their expertise in complex areas of organic chemistry and their contribution to our clients’ optimization and medicinal chemistry programs.”
“Oxeltis’ strength lies in our chemists’ strong know-how. They have developed the skills to tackle the challenges encountered in the long and complex multi-step synthesis of products with multiple chiral centers used in medicinal chemistry,” said Jean-Christophe Meillon, co-founder and director of medicinal chemistry at Oxeltis.
In 2013 Oxeltis experienced an increase in business with longer-term contracts of 6 to 12 months. These contracts supported optimization programs for biotechnology and major pharmaceutical companies. In 2015 Oxeltis was able to expand its business by offering competitive services after an improvement in the euro/dollar exchange rate. The company’s strong presence at international trade shows and major business events has also supported the increase in the company’s revenue.
“The Deloitte In Extenso Technology Fast 50 ranking is a measure of investor and market confidence that demonstrates the vitality and capacity for innovation of French businesses. We are convinced that technology businesses will be the future powerhouse of our economy and the catalysts for driving growth that creates jobs and value,” said Laurent Halfon, Technology Fast 50 lead partner at Deloitte.
Oxeltis generated €845,000 ($899K) in revenue in 2014 and expects to achieve €1.3million ($1.39m) in 2015. It anticipates growth of 50% for 2014-2015.
Entry criteria for the Technology Fast 50 award:
• An independent French company
• Hold patents and/or devote at least 5% of the annual turnover to a research and development budget
• In one of the following five activity sectors:
1. Biotech and life sciences
2. Energy and greentech
3. Hardware and electronics
4. Internet, media and telecommunications and networks
5. Computer software and services
• Established before January 1, 2011 and completed at least three twelve-month financial years
• Achieved a minimum turnover of €50,000 ($53K) in 2011
Note: eCommerce, consultancy and training, communication agencies, marketing and design offices that have not developed their own technology are not allowed to participate.
About Oxeltis
Oxeltis is a medicinal chemistry services company founded in Montpellier in 2010 by former researchers at Idenix Pharmaceuticals.
The company has a small-scale custom synthesis business, as well as hit and lead optimization services, mainly in the areas of antivirals, antibiotics and anticancer compounds.
The Oxeltis team comprises 15 experienced medicinal chemists with expertise in particular areas of organic synthesis: nucleosides/nucleotides, modified sugars and oligo/polysaccharides, and macrocycles. The team focuses on speed, quality and confidentiality in the services and collaborative ventures that it develops.
Oxeltis works with European and North American companies as well as research institutions such as MRC, UCL, the University of Cambridge, the French national institute for health and medical research (Inserm) and the French national center for scientific research (CNRS). Over 80% of its business is in international export.
http://www.oxeltis.com/
About the Technology Fast 50 program
The Technology Fast 50 program began in 1995 in San Jose, California, the heart of Silicon Valley, and was then extended to all United States and the United Kingdom, Canada, the Netherlands, Israel and France. It is now present in over 40 countries and regions in the world. It was created to showcase the remarkable contribution of technology companies to grow the economy.
Deloitte also developed three other programs: Fast 500 EMEA, Fast 500 North America and Fast 500 Asia Pacific. http://www.fast50france.com
About Deloitte Deloitte refers to one or more member firms of Deloitte Touche Tohmatsu Limited, a company incorporated under English law (private company limited by guarantee), and its network of member firms constituted as legally separate and independent entities. In France, the professional services of Deloitte SA are provided by its subsidiaries and affiliates. To learn more about the legal structure of Deloitte Touche Tohmatsu Limited and its member firms, visit www.deloitte.com/about
© 2015 Deloitte SAS
About In Extenso
In Extenso is a member of Deloitte and a major player in the field of accountancy in France. With its network of 4,500 staff and 220 branches across the entire country, In Extenso offers company owners, artisans, retailers, professionals and associations a full professional service, benefiting from proximity and the ability to listen and be proactive. Strongly rooted within the French economy, In Extenso is the preferred partner of more than 90,000 customers from all sectors of the economy. In Extenso achieved a turnover of €360 million ($383m) in 2014-2015.
Oxeltis has built a loyal international client base with its highly responsive service, its non-disclosure policy and strong scientific expertise in niche areas of medicinal chemistry
Montpellier, France, November 26, 2015 – Oxeltis, a medicinal chemistry and custom synthesis company, today announces that it has been ranked 30th in the 2015 Deloitte In Extenso Technology Fast 50 for France. The ranking is an award program for the fastest-growing technology businesses, selected on the rate of revenue growth over the last four financial years. Oxeltis grew by 559% between 2011 and 2014, securing its ranking as 30th amongst the 460 businesses that applied this year.
Founded in 2010, Oxeltis specializes in the development of small-scale custom synthesis and in hit and lead optimization programs; predominantly in the areas of antivirals, antibiotics and anticancer agents. The company has grown exponentially over the last four years after developing its custom synthesis business in a small number of niche areas such as the synthesis of natural molecule analogues for therapeutic use, especially anti-infective drugs. Its experienced team gives the company a distinct advantage in the highly competitive international market. Oxeltis has been able to win new business against European and Asian competitors by controlling overall operating costs and developing a simple and responsive organizational structure.
“Five years after it was founded as a medicinal chemistry services company, Oxeltis has gradually expanded its business in the highly competitive European and international markets,” said Jean-Marc Allaire, CEO of Oxeltis. “We are proud to have been selected by Deloitte. Our inclusion acknowledges the work of Oxeltis’ team of chemists. I applaud their expertise in complex areas of organic chemistry and their contribution to our clients’ optimization and medicinal chemistry programs.”
“Oxeltis’ strength lies in our chemists’ strong know-how. They have developed the skills to tackle the challenges encountered in the long and complex multi-step synthesis of products with multiple chiral centers used in medicinal chemistry,” said Jean-Christophe Meillon, co-founder and director of medicinal chemistry at Oxeltis.
In 2013 Oxeltis experienced an increase in business with longer-term contracts of 6 to 12 months. These contracts supported optimization programs for biotechnology and major pharmaceutical companies. In 2015 Oxeltis was able to expand its business by offering competitive services after an improvement in the euro/dollar exchange rate. The company’s strong presence at international trade shows and major business events has also supported the increase in the company’s revenue.
“The Deloitte In Extenso Technology Fast 50 ranking is a measure of investor and market confidence that demonstrates the vitality and capacity for innovation of French businesses. We are convinced that technology businesses will be the future powerhouse of our economy and the catalysts for driving growth that creates jobs and value,” said Laurent Halfon, Technology Fast 50 lead partner at Deloitte.
Oxeltis generated €845,000 ($899K) in revenue in 2014 and expects to achieve €1.3million ($1.39m) in 2015. It anticipates growth of 50% for 2014-2015.
Entry criteria for the Technology Fast 50 award:
• An independent French company
• Hold patents and/or devote at least 5% of the annual turnover to a research and development budget
• In one of the following five activity sectors:
1. Biotech and life sciences
2. Energy and greentech
3. Hardware and electronics
4. Internet, media and telecommunications and networks
5. Computer software and services
• Established before January 1, 2011 and completed at least three twelve-month financial years
• Achieved a minimum turnover of €50,000 ($53K) in 2011
Note: eCommerce, consultancy and training, communication agencies, marketing and design offices that have not developed their own technology are not allowed to participate.
About Oxeltis
Oxeltis is a medicinal chemistry services company founded in Montpellier in 2010 by former researchers at Idenix Pharmaceuticals.
The company has a small-scale custom synthesis business, as well as hit and lead optimization services, mainly in the areas of antivirals, antibiotics and anticancer compounds.
The Oxeltis team comprises 15 experienced medicinal chemists with expertise in particular areas of organic synthesis: nucleosides/nucleotides, modified sugars and oligo/polysaccharides, and macrocycles. The team focuses on speed, quality and confidentiality in the services and collaborative ventures that it develops.
Oxeltis works with European and North American companies as well as research institutions such as MRC, UCL, the University of Cambridge, the French national institute for health and medical research (Inserm) and the French national center for scientific research (CNRS). Over 80% of its business is in international export.
http://www.oxeltis.com/
About the Technology Fast 50 program
The Technology Fast 50 program began in 1995 in San Jose, California, the heart of Silicon Valley, and was then extended to all United States and the United Kingdom, Canada, the Netherlands, Israel and France. It is now present in over 40 countries and regions in the world. It was created to showcase the remarkable contribution of technology companies to grow the economy.
Deloitte also developed three other programs: Fast 500 EMEA, Fast 500 North America and Fast 500 Asia Pacific. http://www.fast50france.com
About Deloitte Deloitte refers to one or more member firms of Deloitte Touche Tohmatsu Limited, a company incorporated under English law (private company limited by guarantee), and its network of member firms constituted as legally separate and independent entities. In France, the professional services of Deloitte SA are provided by its subsidiaries and affiliates. To learn more about the legal structure of Deloitte Touche Tohmatsu Limited and its member firms, visit www.deloitte.com/about
© 2015 Deloitte SAS
About In Extenso
In Extenso is a member of Deloitte and a major player in the field of accountancy in France. With its network of 4,500 staff and 220 branches across the entire country, In Extenso offers company owners, artisans, retailers, professionals and associations a full professional service, benefiting from proximity and the ability to listen and be proactive. Strongly rooted within the French economy, In Extenso is the preferred partner of more than 90,000 customers from all sectors of the economy. In Extenso achieved a turnover of €360 million ($383m) in 2014-2015.